# TRAM2

## Overview
TRAM2, or translocation associated membrane protein 2, is a gene that encodes a transmembrane protein integral to the function of the endoplasmic reticulum (ER) translocon complex. This protein is pivotal in the posttranslational processing of nascent secretory and membrane proteins, facilitating their proper folding and assembly within the ER. As a result, TRAM2 plays a crucial role in maintaining cellular homeostasis and influencing protein synthesis and secretion processes. Notably, TRAM2 is involved in collagen biosynthesis, particularly collagen type I, which is essential for bone structure and function. Beyond its role in protein translocation, TRAM2 is implicated in various cellular processes, including epithelial-mesenchymal transition (EMT), cell migration, and invasion, and is associated with cancer progression through its interactions with pathways such as YAP and regulatory proteins like RBM15B (Pregizer2007Identification; Tan2022YY1Targeted; Li2021A).

## Function
TRAM2 (translocation associated membrane protein 2) is a component of the translocon complex at the endoplasmic reticulum (ER) membrane, where it plays a crucial role in the posttranslational processing of nascent secretory and membrane proteins. It is involved in the proper folding and assembly of proteins within the ER, contributing to cellular homeostasis by influencing protein synthesis and secretion processes (Pregizer2007Identification; Li2021A). 

TRAM2 is particularly important in the context of collagen biosynthesis, as it is implicated in the synthesis and secretion of collagen type I, the most abundant organic component of the bone extracellular matrix. This function is essential for maintaining bone structure and function (Pregizer2007Identification). The protein's activity is regulated in a cell type- and stage-specific manner, particularly in response to bone morphogenetic protein 2 (BMP-2), which modulates its expression during osteoblast differentiation (Pregizer2007Identification). 

In addition to its role in protein translocation, TRAM2 is involved in cellular processes such as epithelial-mesenchymal transition (EMT), cell migration, and invasion, although its expression alone is insufficient to induce tumor formation (Li2021A).

## Clinical Significance
Alterations in the expression of the TRAM2 gene have been implicated in various cancers. In oral squamous cell carcinoma (OSCC), TRAM2 is significantly up-regulated, contributing to increased tumor metastasis. Knockdown of TRAM2 in OSCC cell lines results in decreased cellular migration, invasion, and reduced expression of matrix metalloproteinases, which are associated with cancer cell invasion and metastasis (Fukushima2018Overexpression). In osteosarcoma, TRAM2 expression is higher in cancerous cell lines compared to normal cells, and its downregulation inhibits cell viability and invasion, indicating its role in tumor progression (Xu2022Comprehensive).

TRAM2 is also linked to the YAP signaling pathway, which is involved in cancer aggressiveness. High TRAM2 expression correlates with poor survival in cancer patients and is associated with epithelial-mesenchymal transition (EMT), a process linked to cancer resistance and aggressive behavior (Li2021A). In hepatocellular carcinoma (HCC), TRAM2 promotes cell proliferation and invasion, and its expression is stabilized by RBM15B in an m6A-dependent manner, contributing to drug resistance (Tan2022YY1Targeted). These findings suggest that TRAM2 plays a significant role in cancer progression and could serve as a potential target for therapeutic interventions.

## Interactions
TRAM2 is involved in several interactions that are crucial for its function in protein translocation and cancer progression. It is a component of the translocon complex at the endoplasmic reticulum (ER) membrane, where it plays a role in the posttranslational processing of nascent secretory and membrane proteins. TRAM2 interacts with SERCA2b, a Ca2+ pump, which is necessary for its function in the ER (Li2021A).

In the context of cancer, TRAM2 is identified as a key mediator in YAP-induced oncogenesis. It acts downstream of the YAP pathway, functioning at the posttranscriptional level. TRAM2 is involved in the translation of components in the YAP pathway, contributing to cancer progression through mechanisms like collagen synthesis, which is linked to invasion and metastasis (Li2021A). TRAM2 also interacts with FSTL-1, a protein involved in epithelial-mesenchymal transition (EMT), affecting its protein levels without altering mRNA levels (Li2021A).

In hepatocellular carcinoma, TRAM2 is regulated by RBM15B, an RNA-binding protein that enhances TRAM2 expression in an m6A-dependent manner. RBM15B interacts with the 3'-untranslated region (UTR) of TRAM2 mRNA, suggesting a direct regulatory relationship (Tan2022YY1Targeted). These interactions highlight TRAM2's role in both protein translocation and cancer-related pathways.


## References


[1. (Pregizer2007Identification) Steven Pregizer, Artem Barski, Charles A. Gersbach, Andrés J. García, and Baruch Frenkel. Identification of novel runx2 targets in osteoblasts: cell type‐specific bmp‐dependent regulation of tram2. Journal of Cellular Biochemistry, 102(6):1458–1471, May 2007. URL: http://dx.doi.org/10.1002/jcb.21366, doi:10.1002/jcb.21366. This article has 17 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcb.21366)

[2. (Fukushima2018Overexpression) Reo Fukushima, Atsushi Kasamatsu, Dai Nakashima, Morihiro Higo, Kazuaki Fushimi, Hiroki Kasama, Yosuke Endo-Sakamoto, Masashi Shiiba, Hideki Tanzawa, and Katsuhiro Uzawa. Overexpression of translocation associated membrane protein 2 leading to cancer-associated matrix metalloproteinase activation as a putative metastatic factor for human oral cancer. Journal of Cancer, 9(18):3326–3333, 2018. URL: http://dx.doi.org/10.7150/jca.25666, doi:10.7150/jca.25666. This article has 21 citations and is from a peer-reviewed journal.](https://doi.org/10.7150/jca.25666)

[3. (Tan2022YY1Targeted) Chunzhong Tan, Peng Xia, Hao Zhang, Kequan Xu, Pengpeng Liu, Deliang Guo, and Zhisu Liu. Yy1-targeted rbm15b promotes hepatocellular carcinoma cell proliferation and sorafenib resistance by promoting tram2 expression in an m6a-dependent manner. Frontiers in Oncology, April 2022. URL: http://dx.doi.org/10.3389/fonc.2022.873020, doi:10.3389/fonc.2022.873020. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fonc.2022.873020)

[4. (Xu2022Comprehensive) Fangxing Xu, Jinglong Yan, Zhibin Peng, Jingsong Liu, and Zecheng Li. Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma. Frontiers in Immunology, December 2022. URL: http://dx.doi.org/10.3389/fimmu.2022.1096009, doi:10.3389/fimmu.2022.1096009. This article has 13 citations and is from a peer-reviewed journal.](https://doi.org/10.3389/fimmu.2022.1096009)

[5. (Li2021A) Li Li, Alejandro P. Ugalde, Colinda L. G. J. Scheele, Sebastian M. Dieter, Remco Nagel, Jin Ma, Abhijeet Pataskar, Gozde Korkmaz, Ran Elkon, Miao-Ping Chien, Li You, Pin-Rui Su, Onno B. Bleijerveld, Maarten Altelaar, Lyubomir Momchev, Zohar Manber, Ruiqi Han, Pieter C. van Breugel, Rui Lopes, Peter ten Dijke, Jacco van Rheenen, and Reuven Agami. A comprehensive enhancer screen identifies tram2 as a key and novel mediator of yap oncogenesis. Genome Biology, January 2021. URL: http://dx.doi.org/10.1186/s13059-021-02272-8, doi:10.1186/s13059-021-02272-8. This article has 16 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1186/s13059-021-02272-8)